PSTX (Poseida Therapeutics) Market Value to Book Value Ratio

Official company branding of Poseida Therapeutics (PSTX)

Poseida Therapeutics (PSTX) combines an academic elite of biologists with a heavy reliance on third-party CDMO manufacturers. The history of the price-to-book ratio shows that the parameter reaches 10.62. A high barrier to entry in the sector is ensured by unique patents for non-viral gene delivery and the complexity of drug synthesis.

Poseida Corp (PSTX): Capitalization to Book Value Ratio from 07/04/2022 to 01/18/2025

Financial and market metric breakdowns for Poseida Therapeutics Inc (PSTX)

- price and consensus price forecast:
Stock Quotes Poseida Therapeutics|PSTX - Broker Consensus Forecast
- market capitalization data:
Market Value Poseida|PSTX - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Poseida Therapeutics|PSTX - Accounting Capitalization|Market Capitalization to Book Value Ratio poseida.com|PSTX - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Poseida Therapeutics|PSTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Poseida|PSTX - Company Debts|Debt to Book Capitalization Ratio Poseida|PSTX - Long-Term Debt|Company Short-Term Debts Poseida Therapeutics
Fundamental valuation:Poseida Therapeutics
Brand item of Poseida

Asset managers require an objective assessment of the premium paid for an asset relative to its tangible assets. This ratio compares the company's market value to its net equity, revealing management efficiency. Analyzing the relationship between market capitalization and book value allows for the determination of the extent to which quotes are inflated. For Poseida Therapeutics (PSTX), this gap reflects market expectations for non-viral gene delivery. Bioengineering innovations create a high premium over the value of physical assets.

Competitor analysis

Market Cap to Net Assets Ratio Legend Biotech|SANA (sana.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio AUTL (Autolus Therapeutics plc)|Market-to-Book Ratio ALLO|Market Value to Book Value Ratio Cartesian Therapeutics Inc RNAC|Capitalization to Book Value Ratio cellectis.com (CLLS)|Caribou Biosciences - Market Capitalization to Book Value Ratio|instilbio.com - Market Cap to Net Assets Ratio|GNTA (Genenta) - Market Value to Book Value Ratio|IPSC: Market-to-Book Ratio|jaspertherapeutics.com (JSPR) - Market Value to Book Value Ratio|SNTI (Senti Biosciences) - Market Value to Book Value Ratio|Market Value to Book Value Ratio ADAP (Adaptimmune Therapeutics plc)|Market-to-Book Ratio CERo Therapeutics Holdings Inc.|TCRT: Market Capitalization to Book Value Ratio|Market Value to Equity Ratio achillestx.com ACHL|CRGX: Market Cap to Net Assets Ratio|TSVT - Market-to-Book Ratio|Market Cap to Net Assets Ratio Gracell Biotechnologies (GRCL)